Annex Advisory Services LLC Acquires 13,692 Shares of LeMaitre Vascular, Inc. $LMAT

Key Points

• Annex Advisory Services LLC increased its stake in LeMaitre Vascular by 6.0% in Q4, acquiring 13,692 shares to hold 243,709 shares (about a 1.07% stake) valued at roughly $19.77 million per its SEC filing.
• Insider selling accelerated: CEO George W. Lemaitre sold 150,000 shares for about $16.01 million, and insiders sold 215,438 shares totaling $23.06 million over the last three months, leaving insiders with 9.50% ownership.
• LeMaitre beat Q4 estimates (EPS $0.68 vs. $0.67; revenue $64.45M vs. $62.98M), raised its quarterly dividend to $0.25 (annualized $1.00, yield 0.9%), and issued FY2026 guidance of $2.81–$3.01 EPS; analysts' consensus is a Moderate Buy with a $105.80 target.

Annex Advisory Services LLC grew its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 6.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 243,709 shares of the medical instruments supplier's stock after acquiring an additional 13,692 shares during the period. Annex Advisory Services LLC owned about 1.07% of LeMaitre Vascular worth $19,765,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. First Trust Advisors LP raised its stake in shares of LeMaitre Vascular by 35.4% during the third quarter. First Trust Advisors LP now owns 828,947 shares of the medical instruments supplier's stock valued at $72,541,000 after acquiring an additional 216,919 shares during the last quarter. Congress Asset Management Co. raised its stake in LeMaitre Vascular by 5.8% during the fourth quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier's stock worth $59,392,000 after buying an additional 40,065 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in LeMaitre Vascular by 0.4% during the third quarter. Dimensional Fund Advisors LP now owns 462,679 shares of the medical instruments supplier's stock worth $40,486,000 after buying an additional 1,677 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in LeMaitre Vascular by 27.0% during the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier's stock worth $22,019,000 after buying an additional 55,804 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its stake in LeMaitre Vascular by 14.1% during the second quarter. Ameriprise Financial Inc. now owns 231,282 shares of the medical instruments supplier's stock worth $19,208,000 after buying an additional 28,556 shares during the last quarter. Institutional investors own 84.64% of the company's stock.

Wall Street Analysts Forecast Growth

LMAT has been the subject of a number of analyst reports. Citizens Jmp lifted their target price on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the stock a "market outperform" rating in a research note on Thursday, February 26th. Wells Fargo & Company lifted their target price on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 26th. Weiss Ratings raised shares of LeMaitre Vascular from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, March 10th. Roth Mkm reissued a "buy" rating and set a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Finally, Freedom Capital upgraded shares of LeMaitre Vascular to a "hold" rating in a report on Tuesday, March 31st. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $105.80.

Insider Activity

In other news, CEO George W. Lemaitre sold 150,000 shares of LeMaitre Vascular stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $106.76, for a total transaction of $16,014,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,532,304 shares in the company, valued at $163,588,775.04. This trade represents a 8.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Trent G. Kamke sold 1,044 shares of LeMaitre Vascular stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $110.29, for a total transaction of $115,142.76. Following the transaction, the insider owned 6,677 shares of the company's stock, valued at $736,406.33. This represents a 13.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 215,438 shares of company stock worth $23,062,911 over the last three months. 9.50% of the stock is currently owned by insiders.

LeMaitre Vascular Trading Up 1.9%

NASDAQ:LMAT opened at $117.39 on Wednesday. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of 46.77, a PEG ratio of 3.32 and a beta of 0.67. The firm has a fifty day simple moving average of $103.02 and a two-hundred day simple moving average of $91.82. LeMaitre Vascular, Inc. has a 12 month low of $78.01 and a 12 month high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.01. The business had revenue of $64.45 million during the quarter, compared to analysts' expectations of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The business's quarterly revenue was up 15.7% on a year-over-year basis. During the same period last year, the company posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th were issued a dividend of $0.25 per share. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Thursday, March 12th. LeMaitre Vascular's dividend payout ratio is 39.84%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.